Former AstraZeneca exec takes over as CEO of $660M Fort Myers lab firm

Fort Myers-based cancer-focused genetic testing services firm NeoGenomics made two key announcements earlier in April. It completed a CEO succession plan announced in January and closed an acquisition to buy a New Jersey lab firm. 

Publicly traded NeoGenomics, which bills itself as a “leading provider of oncology diagnostic solutions that enable precision medicine,” had $660.55 million in revenue in 2024. 

On the CEO transition, diagnostics and biopharma executive Tony Zook took over the position from Chris Smith, effective April 1. Zook, on the company’s board since 2023, was most recently a partner with Lucius Partners, a specialized health care consultancy providing financial, strategic, product development and operational insights to emerging biopharmaceutical and medical device companies. Prior to that and some other roles, Zook was a top official at pharmaceutical giant AstraZeneca, where he held global P&L responsibility for all of AZ's brands and markets, representing over $30 billion in revenues, the company says.